Evidence map›Paper›PMID 24642624›Full record

ArticleBritish journal of cancer2014

Breast cancer metastasis suppressor-1 promoter methylation in cell-free DNA provides prognostic information in non-small cell lung cancer.

I Balgkouranidou, M Chimonidou, G Milaki, E G Tsarouxa, S Kakolyris, D R Welch, V Georgoulias, E S Lianidou

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of cancer, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed, 2 pooled it
4.0field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

50 citing papers in PubMed, 2 syntheses or guidelines pooled it, 82 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Review
  6. Relationship between exosomes and cancer: formation, diagnosis, and treatment.International journal of biological sciences · 2025
    Review
  7. Biomolecules · 2024
    Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

I Balgkouranidou1] Analysis of Circulating Tumor Cells Lab, Laboratory of Analytical Chemistry, Department of Chemistry, University of Athens, 15771 Athens, Greece [2] Department of Medical Oncology, Medical School, Democritus University of Thrace, Alexandroupolis, Greece.
M ChimonidouAnalysis of Circulating Tumor Cells Lab, Laboratory of Analytical Chemistry, Department of Chemistry, University of Athens, 15771 Athens, Greece.
G MilakiDepartment of Medical Oncology, University Hospital of Heraklion, Medical School, University of Crete, Heraklion, Greece.
E G Tsarouxa7th Pulmonology Clinic, 'Sotiria' General Hospital for Chest Diseases, 11526 Athens, Greece.
S KakolyrisDepartment of Medical Oncology, Medical School, Democritus University of Thrace, Alexandroupolis, Greece.
D R WelchDepartment of Cancer Biology, University of Kansas Medical Center, University of Kansas Cancer Center, 3901 Rainbow Boulevard, MS-1071, Kansas City, KS 66160, USA.
V GeorgouliasDepartment of Medical Oncology, University Hospital of Heraklion, Medical School, University of Crete, Heraklion, Greece.
E S LianidouAnalysis of Circulating Tumor Cells Lab, Laboratory of Analytical Chemistry, Department of Chemistry, University of Athens, 15771 Athens, Greece.
Democritus University of Thrace · GRNational and Kapodistrian University of Athens · GRUniversity of Crete · GRThe University of Kansas Cancer Center · US

Funding

MOLECULAR REGULATION OF BREAST CANCER METASTASISR01CA087728 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI WELCH, DANNY R. · 2000 to 2008
$2.7M
KISS1: Defining Mechanisms for Antimetastatic TherapyR01CA134981 · NCI · UNIVERSITY OF KANSAS MEDICAL CENTER · PI WELCH, DANNY R. · 2009 to 2014
$1.5M
NCI NIH HHS R01 CA087728NCI NIH HHS R01 CA134981
6 · The paper itself

Abstract

backgroundBreast-cancer metastasis suppressor 1 (BRMS1) gene encodes for a predominantly nuclear protein that differentially regulates the expression of multiple genes, leading to suppression of metastasis without blocking orthotropic tumour growth. The aim of the present study was to evaluate for the first time the prognostic significance of BRMS1 promoter methylation in cell-free DNA (cfDNA) circulating in plasma of non-small cell lung cancer (NSCLC) patients. Towards this goal, we examined the methylation status of BRMS1 promoter in NSCLC tissues, matched adjacent non-cancerous tissues and corresponding cfDNA as well as in an independent cohort of patients with advanced NSCLC and healthy individuals.

methodsMethylation of BRMS1 promoter was examined in 57 NSCLC tumours and adjacent non-cancerous tissues, in cfDNA isolated from 48 corresponding plasma samples, in cfDNA isolated from plasma of 74 patients with advanced NSCLC and 24 healthy individuals.

resultsThe BRMS1 promoter was highly methylated both in operable NSCLC primary tissues (59.6%) and in corresponding cfDNA (47.9%) but not in cfDNA from healthy individuals (0%), while it was also highly methylated in cfDNA from advanced NSCLC patients (63.5%). In operable NSCLC, Kaplan-Meier estimates were significantly different in favour of patients with non-methylated BRMS1 promoter in cfDNA, concerning both disease-free interval (DFI) (P=0.048) and overall survival (OS) (P=0.007). In advanced NSCLC, OS was significantly different in favour of patients with non-methylated BRMS1 promoter in their cfDNA (P=0.003). Multivariate analysis confirmed that BRMS1 promoter methylation has a statistical significant influence both on operable NSCLC patients' DFI time and OS and on advanced NSCLC patients' PFS and OS.

conclusionsMethylation of BRMS1 promoter in cfDNA isolated from plasma of NSCLC patients provides important prognostic information and merits to be further evaluated as a circulating tumour biomarker.

Indexed as

AdultAgedBiomarkers, TumorCarcinoma, Non-Small-Cell LungCpG IslandsDisease-Free SurvivalDNA MethylationDNA, NeoplasmFemaleGene Expression Regulation, NeoplasticHumansKaplan-Meier EstimateMaleMiddle AgedNeoplasm ProteinsNeoplasm StagingBiomarkers, TumorBRMS1 protein, humanDNA, NeoplasmNeoplasm ProteinsRepressor Proteins

Identifiers

PMID24642624
PMCPMC3992488
OpenAlexW1994306447

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.